Stocks and Investing
Stocks and Investing
Fri, September 22, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, September 21, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Alan Carr Maintained (ALNY) at Strong Buy with Increased Target to $125 on, Sep 21st, 2017
Published on 2024-10-25 22:56:31 - WOPRAI, Alan Carr
Alan Carr of Needham, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $85 to $125 on, Sep 21st, 2017.
Alan has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 0 agree with Alan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Alan
- Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $99 on, Friday, September 8th, 2017
Contributing Sources